Cancer Organizations Continue Reform Lobbying: Target Issue Are Off-Label Drugs, Clinical Trials
In Brief: Wells, Gardner, Brennan Lead Surgical Oncology; Young, Flynn, Are New officers For Head & Neck
ACCC Statement, ASCO Comments On Health Reform
DCBDC board Okays RFA concept On AIDS Lymphoma
NIH Issues Interim Guidelines For Research Using fetal Tissue
Cancer Meetings Listed
RFP, RFA Available
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
